Evidence map›Paper›PMID 38745766›Full record

ArticleExploration of targeted anti-tumor therapy2024

Improving single nucleotide polymorphisms genotyping accuracy for dihydropyrimidine dehydrogenase testing in pharmacogenetics.

Annalaura Montella, Sueva Cantalupo, Giuseppe D'Alterio, Vincenzo Damiano, Achille Iolascon, Mario Capasso

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Exploration of targeted anti-tumor therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Annalaura MontellaDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.ORCID https://orcid.org/0000-0003-0858-228X
Sueva CantalupoCEINGE Biotecnologie Avanzate Franco Salvatore, 80145 Naples, Italy.ORCID https://orcid.org/0000-0001-6173-281X
Giuseppe D'AlterioCEINGE Biotecnologie Avanzate Franco Salvatore, 80145 Naples, Italy.
Vincenzo DamianoMedical Oncology, Integrated Activity Department of Onco-Hematological Diseases, Pathological Anatomy and Rheumatic Diseases, AOU Federico II, 80131 Naples, Italy.
Achille IolasconDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.ORCID https://orcid.org/0000-0002-9558-0356
Mario CapassoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.ORCID https://orcid.org/0000-0003-3306-1259

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fluoropyrimidines, crucial in cancer treatment, often cause toxicity concerns even at standard doses. Toxic accumulation of fluoropyrimidine metabolites, culminating in adverse effects, can stem from impaired dihydropyrimidine dehydrogenase (DPYD) enzymatic function. Emerging evidence underscores the role of single nucleotide polymorphisms (SNPs) in

Indexed as

dihydropyrimidine dehydrogenasegenotypingPharmacogenetics

Identifiers

PMID38745766
PMCPMC11090686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.